← Back to all trials
Not Yet Recruiting
NCT07598448
A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain
Conditions: Complement 3 Glomerulopathy
Sex: All
Ages: 18 Years – 100 Years
Healthy volunteers: No
Enrollment: 35
Sponsor: Novartis Pharmaceuticals
Summary
This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.
Eligibility Criteria
Inclusion criteria:
1. Adult patients (≥18 years).
2. Biopsy-confirmed C3G.
3. Patients who have received at least one dose of iptacopan through an EAP from October 2020 to June 2025.
Exclusion criteria:
1\. Patients treated with iptacopan through an EAP for indications other than C3G.
Source: ClinicalTrials.gov (NCT07598448). StuddyBuddy aggregates publicly available trial information.
